Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline" report to their offering.

The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%.

Hypertension prevalence is a prominent contributor to market size in the assessed countries.

The marketed products landscape for hypertension comprises a wide range of treatment options, which includes angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta blockers, renin inhibitors, and diuretics. These are used both as monotherapy and combination therapy (including fixed-dose combinations), and the proportion of patients treated using the various therapy approaches varies from country to country.

The high prevalence of the disease is a substantial contributor to healthcare costs and is a major cause of morbidity. However, awareness of hypertension is low among physicians, patients, and the public, leading to a high level of undiagnosed and untreated cases.

The market is mostly dominated by generics, and there are only a few patented products

- Will generics continue to dominate treatment?

- How do the elderly populations and their associated risk factors affect prevalence?

- What effect will the patent expirations of currently branded therapies have on market value?

The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.

- Which molecular targets appear most frequently in the pipeline?

- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?

- Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?

- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.

- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?

Various drivers and barriers will influence the market over the forecast period.

- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?

- Which factors are most likely to drive the market in these countries?

For more information about this report visit http://www.researchandmarkets.com/research/k9c3qw/antihypertensive

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs